X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with JINDAL SOUTHWEST H - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs JSW HOLDINGS - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES JSW HOLDINGS INDOCO REMEDIES/
JSW HOLDINGS
 
P/E (TTM) x 30.5 71.2 42.9% View Chart
P/BV x 2.4 2.9 83.0% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 INDOCO REMEDIES   JSW HOLDINGS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
JSW HOLDINGS
Mar-18
INDOCO REMEDIES/
JSW HOLDINGS
5-Yr Chart
Click to enlarge
High Rs3602,007 18.0%   
Low Rs2491,515 16.4%   
Sales per share (Unadj.) Rs119.079.9 149.0%  
Earnings per share (Unadj.) Rs8.461.4 13.6%  
Cash flow per share (Unadj.) Rs15.261.4 24.8%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7835.5 8.5%  
Shares outstanding (eoy) m92.1511.10 830.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.622.0 11.6%   
Avg P/E ratio x36.428.7 127.0%  
P/CF ratio (eoy) x20.028.7 69.8%  
Price / Book Value ratio x4.32.1 204.5%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08319,547 143.7%   
No. of employees `0006.0NA 301,800.0%   
Total wages/salary Rs m2,16734 6,410.4%   
Avg. sales/employee Rs Th1,817.0443,250.0 0.4%   
Avg. wages/employee Rs Th359.016,900.0 2.1%   
Avg. net profit/employee Rs Th127.7340,550.0 0.0%   
INCOME DATA
Net Sales Rs m10,968887 1,237.2%  
Other income Rs m407 575.4%   
Total revenues Rs m11,007893 1,232.1%   
Gross profit Rs m1,565836 187.2%  
Depreciation Rs m6330 210,933.3%   
Interest Rs m620-   
Profit before tax Rs m909842 108.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139161 86.1%   
Profit after tax Rs m771681 113.2%  
Gross profit margin %14.394.3 15.1%  
Effective tax rate %15.319.1 79.7%   
Net profit margin %7.076.8 9.1%  
BALANCE SHEET DATA
Current assets Rs m5,7251,409 406.4%   
Current liabilities Rs m5,45420 27,067.5%   
Net working cap to sales %2.5156.6 1.6%  
Current ratio x1.069.9 1.5%  
Inventory Days Days620-  
Debtors Days Days7216 460.0%  
Net fixed assets Rs m5,3071 379,098.6%   
Share capital Rs m184111 166.0%   
"Free" reserves Rs m6,3319,163 69.1%   
Net worth Rs m6,5169,274 70.3%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9709,299 128.7%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.1 961.1%   
Return on assets %7.07.3 95.0%  
Return on equity %11.87.3 161.1%  
Return on capital %12.49.1 136.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886662 134.0%  
From Investments Rs m-1,706-582 292.9%  
From Financial Activity Rs m1,316NA-  
Net Cashflow Rs m49779 626.2%  

Share Holding

Indian Promoters % 59.2 60.9 97.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.5 2,500.0%  
FIIs % 6.0 7.8 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 30.8 72.7%  
Shareholders   12,805 29,821 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   NALWA SONS INV  GREENPLY IND  NESCO LIMITED  CENTURY PLYBOARDS  COMPACT DISC  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

JSW HOLDINGS Announces Quarterly Results (1QFY19); Net Profit Down 75.7% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, JSW HOLDINGS has posted a net profit of Rs 98 m (down 75.7% YoY). Sales on the other hand came in at Rs 127 m (down 75.0% YoY). Read on for a complete analysis of JSW HOLDINGS's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 14, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - IL&FS INV. MANAGERS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS